Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Trials Are Inadequate Response To HCV Drug Concerns – FDA Cmte.

Executive Summary

Skepticism over the utility of Phase IV commitments shaped an FDA advisory committee's recommendations on development of new hepatitis C treatments

You may also be interested in...



FDA Should Fine Companies With Late Post-Marketing Studies, HHS OIG Says

FDA should have the authority to sanction pharmaceutical manufacturers that are not adequately fulfilling their post-marketing commitments, the HHS Office of Inspector General suggests

Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA’s Median Review Time For Novel Drugs Held Steady In 2020

Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel